Tonix Pharmaceuticals

Tonix Pharmaceuticals company information, Employees & Contact Information

Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.

Company Details

Employees
113
Founded
-
Address
26 Main St,
Phone
212-980-9155
Email
jo****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Chatham, New Jersey
Looking for a particular Tonix Pharmaceuticals employee's phone or email?

Tonix Pharmaceuticals Questions

News

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence - Yahoo Finance

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence Yahoo Finance

First New Fibromyalgia Treatment in 15 Years: Tonix Pharma Builds Launch Team for FDA-Approved Tonmya - Stock Titan

First New Fibromyalgia Treatment in 15 Years: Tonix Pharma Builds Launch Team for FDA-Approved Tonmya Stock Titan

First New Fibromyalgia Drug in 15 Years: Tonix's Tonmya Shows Breakthrough Pain Reduction in Phase 3 - Stock Titan

First New Fibromyalgia Drug in 15 Years: Tonix's Tonmya Shows Breakthrough Pain Reduction in Phase 3 Stock Titan

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - Sahm

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase Sahm

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights - Yahoo Finance

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights Yahoo Finance

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash - Yahoo Finance

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash Yahoo Finance

Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID - Tonix Pharmaceuticals

Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID Tonix Pharmaceuticals

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia - Yahoo Finance

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia Yahoo Finance

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual - Yahoo Finance

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual Yahoo Finance

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine - Yahoo Finance

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine Yahoo Finance

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 - Yahoo Finance

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 Yahoo Finance

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals - Yahoo Finance

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals Yahoo Finance

Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires - Yahoo Finance

Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires Yahoo Finance

Tonix Pharmaceuticals Holding Corp. Announces Upcoming Investor Presentations at January Conferences - Quiver Quantitative

Tonix Pharmaceuticals Holding Corp. Announces Upcoming Investor Presentations at January Conferences Quiver Quantitative

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - Yahoo Finance

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting Yahoo Finance

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer - citybiz

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer citybiz

Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision - Stock Titan

Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision Stock Titan

Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split - Yahoo Finance

Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split Yahoo Finance

Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - Yahoo Finance

Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Yahoo Finance

Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting - Yahoo Finance

Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting Yahoo Finance

Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P. - Yahoo Finance

Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P. Yahoo Finance

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring - Yahoo Finance

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring Yahoo Finance

Tonix's Breakthrough Fibromyalgia Drug Takes Major Step Forward with FDA NDA Acceptance - Stock Titan

Tonix's Breakthrough Fibromyalgia Drug Takes Major Step Forward with FDA NDA Acceptance Stock Titan

Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers - Newswire.com

Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers Newswire.com

Top Tonix Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant